APOE {epsilon}4 and bapineuzumab: Infusing pharmacogenomics into Alzheimer disease therapeutics.
Kaufer
Dan
D
Gandy
Sam
S
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000235:genetics* / Q000523:psychology; D016229:Amyloid beta-Peptides / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D053327:Apolipoprotein E4 / Q000235:genetics*; D003071:Cognition / Q000187:drug effects; D006579:Heterozygote; D006801:Humans; D007275:Injections, Intravenous; D016896:Treatment Outcome
D016229:Amyloid beta-Peptides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D053327:Apolipoprotein E4; C545458:bapineuzumab